ECO Animal Health Group (LON:EAH) Stock Price Passes Above 50-Day Moving Average – Here’s What Happened

ECO Animal Health Group plc (LON:EAH)’s share price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 105.69 and traded as high as GBX 113. ECO Animal Health Group shares last traded at GBX 112.45, with a volume of 20,448 shares traded.

Wall Street Analyst Weigh In

Separately, Shore Capital boosted their price target on shares of ECO Animal Health Group from GBX 150 to GBX 160 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of GBX 160.

ECO Animal Health Group Trading Up 1.3%

The business has a 50 day simple moving average of GBX 105.69 and a 200 day simple moving average of GBX 90.36. The company has a debt-to-equity ratio of 4.81, a current ratio of 2.96 and a quick ratio of 2.14. The company has a market cap of £75.44 million, a price-to-earnings ratio of 25.62 and a beta of -0.05.

ECO Animal Health Group (LON:EAH) last announced its earnings results on Monday, December 1st. The company reported GBX (0.54) earnings per share for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 1.27%.

Insider Buying and Selling at ECO Animal Health Group

In related news, insider David Hallas bought 18,348 shares of ECO Animal Health Group stock in a transaction dated Thursday, December 4th. The shares were bought at an average cost of GBX 109 per share, for a total transaction of £19,999.32. Corporate insiders own 11.17% of the company’s stock.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.